World Health Organisation launches 4th edition of Classification of Skin Tumours
31 August 2018
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours. The new edition of WHO Skin Blue books incorporates the most recent developments in skin tumours, including melanoma. This includes new categorisation based on recent genetic information and cliniopathological correlations. This classification will have significant impact of reporting and management of melanoma and melanocytic skin lesions.
These reference books are at an international standard for any medical professional or research professional. This publication has long been regarded by pathologists as the highest standard of reference for the diagnosis of tumours. It is an essential guide for evaluation, clinical trials and cancer studies.
This edition updates and discusses the significant changes to the classification of melanoma, based on the latest information from genetic and molecular studies. It also provides vital information on pathology, genealogy, prognosis and protection for each of the tumour types covered.
Major award for world-leaders in melanoma research
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Melanoma Institute Australia shines at prestigious Cancer Research Awards
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Women of MIA lead the way in melanoma research at SMR
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Immune cell research presented at SMR
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Patients to benefit from updated skin tumour publications
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
SunSafe Student Ambassador Program
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
International collaboration the key to increasing survival
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
Australia's best minds in melanoma research converge on Melbourne
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
Nobel Prize for novel cancer therapies
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
World Health Organisation launches 4th edition of Classification of Skin Tumours
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Support PBS listing for pembrolizumab
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
World Congress on Cancers of the Skin 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia welcomes new CEO Matthew Browne
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Melanoma in Practice: Nurse Conference
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
Reducing the risk of melanoma in young adults
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia launches free e-learning education portal
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.